Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘CTL119’

Standing from the crowd in refractory CLL?

Last year the two FDA approvals of tisagenlecleucel (Novartis) and axicabtagene ciloleucel (Kite/Gilead) CAR T cell therapy for hematologic malignancies such as pediatric acute lymphoblastic leukemia (pALL) and non-Hodgkins lymphoma (NHL) have captured a lot of attention.

It’s worth remembering, however, that back in 2010 the first patient who had a dramatic response to CD19 targeted CAR T cell therapy was actually a gentleman with advanced chronic lymphocytic leukemia (CLL), the case study of which was subsequently published by Porter et al., (2011) in the New England Journal of Medicine.

We’ve been following CAR T cell therapy and its potential in CLL for some time now, with all the successes, trials and tribulations along the way.

Dr David Porter (Penn) told BSB earlier this month:

“The very first patients we treated are now eight years out from their infusion, a little over eight years, and still in remission, still doing extremely well with no evidence of disease or progression, never had any other therapy. So, I think it’s become very clear that for some patients this is effective in the far advanced setting.”

It’s now two years since we last spoke and it was a great pleasure to reconnect with Dr Porter. As he told BSB at ASH in San Diego:

“One way you make it better is to understand why it’s working and why it’s not.”

What have we since learnt about the potential for adoptive cellular therapy in CLL and what new insights did we gain from new data presented at ASH18? The answers may well surprise you.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

A warm welcome for Nobel Laureate Dr Jim Allison at CICON18

With all the furore and excitement over Dr Jim Allison’s Nobel prize award that hit CICON18 on Monday, it would be fair to say it was the highlight of the conference for many and it was pretty cool to be there in New York at the time.

Aside from the external news, there were also some intriguing developments to report on the CAR T cell therapy front – you might be forgiven for thinking that there’s not much new to say with two products now approved, but I have to point out that this is a very active area of research and there’s much going on here that is well worth highlighting.

Cell therapy is a bit like the twilight zone in the city that never sleeps – there’s a different vibe and energy about this particular research niche in oncology and quite a few new developments to discuss…

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Chicago RiverAlthough ASH and ASGCT are important meetings for CAR T cell therapies, there are still some intriguing data to be had at ASCO next month, including both oral and poster abstracts.

In our latest ASCO 2017 Preview, we take a look at what to expect from in the CAR T cell space.

Subscribers can login to read our latest insights and analysis

This content is restricted to subscribers

Sunny Day in Orlando, FL

Orlando, FL was the place to be last week thanks to two specialist meetings in town: BMT Tandem 2017 #BMTTandem17 (joint meeting of ASBMT and CIBMTR), and the inaugural ASCO-SITC Clinical Immuno-Oncology Symposium #Immunosym.  Indeed, several speakers spoke at both events!

Throughout this week we’ll be writing about the insights we gained from the two meetings into the latest data and trends in immunotherapy, immuno-oncology and adoptive cell therapy.

We’re kicking off with cell therapy insights from the BMT Tandem Meeting. It’s the joint meeting of the American Society for Blood and Marrow Transplantation and Center for International Blood & Marrow Transplant Research. If you don’t already, do follow the ASBMT President for 2017-2018 Dr Krishna Komanduri, @drkomanduri. He’s actively involved in CAR T cell therapy trials in Miami.

It’s worth remembering that bone marrow transplanters led the way in the use of immunotherapy to provide cures for cancer. Today, the BMT transplant community are pioneering adoptive cell therapy, and in particular  CAR T cell therapy in multiple hematologic malignancies including ALL, NHL, CLL and Multiple Myeloma. This makes the annual BMT Tandem meeting one to watch for some of the latest cell therapy data.

Subscribers can login to read what we learnt from #BMTTandem17

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!